Thrombopoietin Receptor Agonists Platelet Growth Factors

oncology patients have been shown to benefi t from CSF usage if there is ≥20 risk of neutro- penia or if neutropenia has occurred with previous courses of chemotherapy. Similarly there is a ben- efi t to CSF utilization in high-risk febrile neutro- penia by decreasing the days of neutropenia and the total length of hospitalization although there has been no proven benefi t in overall survival. Similarly there is potential benefi t of CSFs in dose-intensity regimens such as compressed Ewing sarcoma therapy by preventing delay in chemotherapy delivery. Utilization of erythropoi- etin is not recommended but may be considered in the patient with a contraindication to red blood cell transfusion. Platelet growth factors should not be utilized in pediatric patients with chemother- apy-induced thrombocytopenia. References Aapro MS, Bohlius J, Cameron DA et al 2011 2010 Update of EORTC Guidelines for the use of granulocyte- colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutrope- nia in adult patients with lymphoproliferative disor- ders and solid tumors. Eur J Cancer 47:8–32 Aapro M, Jeklmann W, Constantinescu SN, Leyland- Jones B 2012 Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progres- sion in cancer. Br J Cancer 106:1249–1258 Abdelrazik N, Fouda M 2007 Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. Hematology 12:533–541 Alonzo TA, Kobrinsky NL, Aledo A et al 2002 Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol 24:627–635 Andemariam B, Psaila B, Bussel JB 2007 Novel throm- bopoietic agents. Hematology Am Soc Hematol Educ Program 106–113 André N, Kababri ME, Bertrand P et al 2007 Safety and effi cacy of pegfi lgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 18:277–281 Angiolillo AL, Davenport V, Bonilla MA et al 2005 A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refrac- tory solid tumors: a Children’s Oncology Group expe- rience. Clin Cancer Res 11:2644–2650 Antman KS, Griffi n JD, Elias A et al 1988 Effect of recombinant human granulocyte-macrophage colony- stimulating factor on chemotherapy-induced myelo- suppression. N Engl J Med 319:593–598 Basser RL, Rasko JE, Clarke K et al 1997 Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and devel- opment factor with fi lgrastim after dose-intensive che- motherapy in patients with advanced cancer. Blood 89:3118–3128 Basser RL, Underhill C, Davis I et al 2000 Enhancement on platelet recovery after myelosuppressive chemo- therapy by recombinant human megakaryocyte growth and development factor in patients with advanced can- cer. J Clin Oncol 18:2852–2861 Basser RL, O’Flaherty E, Green M et al 2002 Development of pancytopenia with neutralizing anti- bodies to thrombopoietin after multicycle chemother- apy supported by megakaryocyte growth and development factor. Blood 99:2599–2602 Batra S, Perelman N, Luck LR et al 2003 Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 83:1477–1487 Bennett CL, Silver SM, Djulbegovic B et al 2008 Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914–924 Bhatia M, Davenport V, Cairo MS 2007 The role of interleukins-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lym- phoma, acute myeloid leukemia and bone marrow fail- ure syndromes. Leuk Lymphoma 48:9–15 Blumer J, Berg S, Adamson PC et al 2007 Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pedi- atric patients with chemotherapy- induced anemia. Pediatr Blood Cancer 49:687–693 Bohlius J, Wilson J, Seidenfeld J et al 2006 Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714 Bohlius J, Schmidlin K, Brillant C et al 2009 Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta- analysis of randomized trials. Lancet 373:1532–1542 Bohlius J, Schmidlin K, Brillant C et al 2010 Erythropoietin or darbepoetin for patients with can- cer—meta-analysis based on individual patient data. Cochrane Database Syst Rev 3:CD007303 Bokemeyer C 2004 EORTC guidelines for the use of erythropoietic proteins in anaemic patients with can- cer. Eur J Cancer 40:2201–2216 Bonadonna G, Valagussa P 1981 Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15 Borinstein SC, Pollard J, Winter L, Hawkins DS 2009 Pegfi lgrastim for prevention of chemotherapy- associated neutropenia in pediatric patients with solid tumors. Pediatr Blood Cancer 53:375–378 15 Hematopoietic Growth Factors